163 related articles for article (PubMed ID: 33790108)
21. Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity.
Domanski TL; He YA; Khan KK; Roussel F; Wang Q; Halpert JR
Biochemistry; 2001 Aug; 40(34):10150-60. PubMed ID: 11513592
[TBL] [Abstract][Full Text] [Related]
22. Comparison of CYP3A4 and CYP3A5: the effects of cytochrome b5 and NADPH-cytochrome P450 reductase on testosterone hydroxylation activities.
Lee SJ; Goldstein JA
Drug Metab Pharmacokinet; 2012; 27(6):663-7. PubMed ID: 22785258
[TBL] [Abstract][Full Text] [Related]
23. Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth.
Lacroix D; Sonnier M; Moncion A; Cheron G; Cresteil T
Eur J Biochem; 1997 Jul; 247(2):625-34. PubMed ID: 9266706
[TBL] [Abstract][Full Text] [Related]
24. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
Yamazaki H; Shimada T
Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
[TBL] [Abstract][Full Text] [Related]
25. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.
Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Honda G; Nakagawa K; Ishizaki T; Kamataki T
Drug Metab Pharmacokinet; 2004 Apr; 19(2):120-9. PubMed ID: 15499178
[TBL] [Abstract][Full Text] [Related]
26. Stereoselective Oxidation Kinetics of Deoxycholate in Recombinant and Microsomal CYP3A Enzymes: Deoxycholate 19-Hydroxylation Is an In Vitro Marker of CYP3A7 Activity.
Chen YJ; Zhang J; Zhu PP; Tan XW; Lin QH; Wang WX; Yin SS; Gao LZ; Su MM; Liu CX; Xu L; Jia W; Sevrioukova IF; Lan K
Drug Metab Dispos; 2019 Jun; 47(6):574-581. PubMed ID: 30918015
[TBL] [Abstract][Full Text] [Related]
27. alpha-Naphthoflavone acts as activator and reversible or irreversible inhibitor of rabbit microsomal CYP3A6.
Boek-Dohalská L; Hodek P; Sulc M; Stiborová M
Chem Biol Interact; 2001 Oct; 138(1):85-106. PubMed ID: 11640917
[TBL] [Abstract][Full Text] [Related]
28. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
Williams JA; Ring BJ; Cantrell VE; Jones DR; Eckstein J; Ruterbories K; Hamman MA; Hall SD; Wrighton SA
Drug Metab Dispos; 2002 Aug; 30(8):883-91. PubMed ID: 12124305
[TBL] [Abstract][Full Text] [Related]
29. Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide).
Tseng E; Walsky RL; Luzietti RA; Harris JJ; Kosa RE; Goosen TC; Zientek MA; Obach RS
Drug Metab Dispos; 2014 Jul; 42(7):1163-73. PubMed ID: 24737844
[TBL] [Abstract][Full Text] [Related]
30. In vitro assessments predict that CYP3A4 contributes to a greater extent than CYP3A5 to prednisolone clearance.
Skauby RH; Bergan S; Andersen AM; Vethe NT; Christensen H
Basic Clin Pharmacol Toxicol; 2021 Dec; 129(6):427-436. PubMed ID: 34396687
[TBL] [Abstract][Full Text] [Related]
31. Variability of CYP3A7 expression in human fetal liver.
Leeder JS; Gaedigk R; Marcucci KA; Gaedigk A; Vyhlidal CA; Schindel BP; Pearce RE
J Pharmacol Exp Ther; 2005 Aug; 314(2):626-35. PubMed ID: 15845858
[TBL] [Abstract][Full Text] [Related]
32. Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones.
Niwa T; Yabusaki Y; Honma K; Matsuo N; Tatsuta K; Ishibashi F; Katagiri M
Xenobiotica; 1998 Jun; 28(6):539-47. PubMed ID: 9667077
[TBL] [Abstract][Full Text] [Related]
33. Thin-layer chromatography analysis of human CYP3A-catalyzed testosterone 6beta-hydroxylation.
Waxman DJ; Chang TK
Methods Mol Biol; 2006; 320():133-41. PubMed ID: 16719384
[TBL] [Abstract][Full Text] [Related]
34. Inhibitory anti-CYP3A4 peptide antibody: mapping of inhibitory epitope and specificity toward other CYP3A isoforms.
Wang RW; Newton DJ; Liu NY; Shou M; Rushmore T; Lu AY
Drug Metab Dispos; 1999 Feb; 27(2):167-72. PubMed ID: 9929498
[TBL] [Abstract][Full Text] [Related]
35. Assessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes.
Mugundu GM; Sallans L; Guo Y; Shaughnessy EA; Desai PB
Drug Metab Dispos; 2012 Feb; 40(2):389-96. PubMed ID: 22096084
[TBL] [Abstract][Full Text] [Related]
36. Helices F-G are important for the substrate specificities of CYP3A7.
Torimoto N; Ishii I; Toyama K; Hata M; Tanaka K; Shimomura H; Nakamura H; Ariyoshi N; Ohmori S; Kitada M
Drug Metab Dispos; 2007 Mar; 35(3):484-92. PubMed ID: 17178770
[TBL] [Abstract][Full Text] [Related]
37. Dehydroepiandrosterone 7alpha- and 7beta-hydroxylation in mouse brain microsomes. Effects of cytochrome P450 inhibitors and structure-specific inhibition by steroid hormones.
Doostzadeh J; Cotillon AC; Morfin R
J Neuroendocrinol; 1997 Dec; 9(12):923-8. PubMed ID: 9468017
[TBL] [Abstract][Full Text] [Related]
38. Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7.
Yamaori S; Yamazaki H; Suzuki A; Yamada A; Tani H; Kamidate T; Fujita Ki; Kamataki T
Biochem Pharmacol; 2003 Dec; 66(12):2333-40. PubMed ID: 14637191
[TBL] [Abstract][Full Text] [Related]
39. Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5.
Tang LWT; Verma RK; Yong RP; Li X; Wang L; Lin Q; Fan H; Chan ECY
Mol Pharmacol; 2021 Sep; 100(3):224-236. PubMed ID: 34210765
[TBL] [Abstract][Full Text] [Related]
40. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism.
Mei Q; Tang C; Assang C; Lin Y; Slaughter D; Rodrigues AD; Baillie TA; Rushmore TH; Shou M
J Pharmacol Exp Ther; 1999 Nov; 291(2):749-59. PubMed ID: 10525096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
